Novartis Access started in September 2015. The program has since launched in Kenya and memoranda of understanding have been signed with Ethiopia and Rwanda. In addition, advanced discussions are taking place to introduce the program in more than 10 countries in Africa, Asia, Latin America and the Commonwealth of Independent States (CIS).
As we are aiming to continuously improve the program, Boston University has developed a methodology to evaluate Novartis Access in Kenya that could lead to an industry benchmark. Together with Management Sciences for Health, we have also undertaken a supply chain integrity analysis in 22 healthcare facilities in the country.
In early 2017, we published our Novartis Access one-year report. It describes first results, early learnings and challenges from our first twelve months on the ground, and provides external perspectives.
*The patient number was calculated based on treatment delivered and the following elements: daily treatment doses, treatment duration, treatment adherence and potential treatment overlap (as it is common for NCD patients to take several drugs).
The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.